Falcarindiol induces apoptosis, ROS accumulation, and cell cycle arrest via EGFR/mTOR pathway modulation: an integrated in silico and in vitro study in cervical cancer

Submitted by Anonymous on

AbstractBackground Falcarindiol, a bioactive polyacetylene, has shown cytotoxic effects in several cancers including breast, colorectal, and oral squamous carcinoma, but its pharmacological actions in cervical cancer are not well defined. Objectives This study aims to integrate in silico approaches to...

Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM)

Submitted by Anonymous on

Progression-free survival (PFS) with first-line third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors remains suboptimal in EGFR L858R-mutated advanced non-small-cell lung cancer (NSCLC), highlighting a need for strategies to delay resistance. This single-arm, phase II study (FIRM; ChiCTR2200060897) evaluates...

Ensemble learning strategy-based 18 F-FDG PET/CT metabolic habitats radiomics for predicting EGFR mutation and prognosis in LA-NSCLC: a multi-center study

Submitted by Anonymous on

AbstractBackground Epidermal growth factor receptor (EGFR) status critically guides tyrosine kinase inhibitor therapy in locally advanced non-small cell lung cancer (LA-NSCLC). This study aimed to develop and validate an 18 F-FDG PET/CT-based stacking ensemble model leveraging metabolic habitat radiomics to...

Savolitinib/Osimertinib Extends PFS in MET-Amplified EGFR-Mutated NSCLC

Submitted by Anonymous on

Savolitinib/Osimertinib Extends PFS in MET-Amplified EGFR-Mutated NSCLC A new study reveals that savolitinib and osimertinib significantly enhance survival in advanced EGFR-mutated lung cancer, outperforming traditional chemotherapy. The combination of savolitinib (Orpathys) and osimertinib (Tagrisso) significantly improves progression-free survival (PFS) compared...

A large language model-guided reinforcement learning framework for EGFR anticancer drug design

Submitted by Anonymous on

Abstract We introduce a generative drug-design framework that combines large chemical language models (CLMs) pretraining, target specific masked-language fine-tuning, and reinforcement learning (RL) to create novel small molecule inhibitors of EGFR. Using a multi-objective reward that balances predicted potency, drug-likeness,...

Favorable response to third-generation TKI furmonertinib in a patient with early-stage non-small cell lung cancer harboring rare compound EGFR mutations: Exon 18 G719C and Exon 20 S768I - A Case Report

Submitted by Anonymous on

EGFR Exon 19 deletions and exon 21 point mutations of EGFR are the most prevalent alterations in lung adenocarcinoma, and patients with these mutations deriv 1 Introduction The prevalence of epidermal growth factor receptor (EGFR) mutations in non-small cell lung...

ALX Oncology Spotlights Evorpacept HER2 Strategy and EGFR ADC ALX2004 Progress at JPM Conference

Submitted by Anonymous on

ALX Oncology NASDAQ: ALXO outlined progress across its two clinical-stage programs-CD47 blocker evorpacept and EGFR-targeted antibody-drug conjugate (ADC) ALX2004-during a presentation at the J.P. Morgan conference led by CEO Jason Lettmann and Chief Medical Officer Barbara Klencke. Management highlighted what...

[225Ac]Ac-labeled matuzumab is an effective radioimmunotherapeutic against EGFR-positive triple negative breast cancer

Submitted by Anonymous on

AbstractBackground EGFR is overexpressed in TNBC, and “naked” anti-EGFR monoclonal antibodies have been evaluated in clinical trials with dismal effectiveness. Matuzumab is an anti-EGFR monoclonal antibody that can be used to develop theranostics. We posit that compared with “naked” antibodies,...

Subscribe to Newsfeed